8-K
GridAI Technologies Corp. (GRDX)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):August 21, 2024
| Entero Therapeutics, Inc. | ||
|---|---|---|
| (Exact name of registrant as specified in its charter) | ||
| Delaware | 001-37853 | 46-4993860 |
| --- | --- | --- |
| (State or other jurisdiction of<br><br> incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 777 Yamato Road, Suite 502<br><br> <br>Boca Raton, Florida | 33431 | |
| --- | --- | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including
area code: (561) 589-7020
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| --- | --- |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| --- | --- |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| --- | --- |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which<br><br> registered |
|---|---|---|
| Common Stock, par value $0.0001 per share | ENTO | Nasdaq<br> Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 3.01 | Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
|---|
As previously reported in a Form 12b-25 Notification of Late Filing filed by Entero Therapeutics, Inc. (the “Company”), on August 15, 2024, the Company is delayed in filing its Quarterly Report on Form 10-Q for the period ended June 30, 2024 (the “Form 10-Q”) with the U.S. Securities and Exchange Commission (the “SEC”) because it is in the process of engaging a new independent registered public accounting firm.
On August 21, 2024, the Company received a notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that, because the Company has not timely filed its Form 10-Q, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires companies with securities listed on Nasdaq to timely file all required periodic reports with the SEC. The Company has sixty (60) days, or until October 21, 2024, to submit a plan to regain compliance with the Rule to Nasdaq. If Nasdaq approves such a plan, it has the discretion to grant the Company an extension of up to 180 calendar days, or until February 17, 2025, to regain compliance with the Rule. The Notice has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Capital Market. The Company is in the process of engaging a new independent registered public accounting firm and intends to take the necessary steps to regain compliance with the Rule as soon as practicable.
On August 23, 2024, the Company issued a press release announcing its receipt of the Notice (the “Press Release”). The Press Release is attached hereto as Exhibit 99.1 and is being filed herewith.
| Item 9.01 | Financial Statements and Exhibits. |
|---|---|
| 99.1 | Press Release, dated August 23, 2024 |
| --- | --- |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Entero Therapeutics, Inc. | ||
|---|---|---|
| August 23, 2024 | By: | /s/ James Sapirstein |
| Name: | James Sapirstein | |
| Title: | Chief Executive Officer |
Exhibit 99.1
Entero Therapeutics, Inc. Receives Nasdaq NotificationRegarding Delayed Form 10-Q
BOCA RATON, Fla., August 23, 2024 (GLOBE NEWSWIRE) – Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) advising that, because the Company failed to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 (the “Form 10-Q”), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”). Nasdaq has informed the Company that it has until October 21, 2024, to submit a plan to regain compliance with the Rule. If Nasdaq approves the Company’s plan, it has the discretion to grant the Company an extension of up to 180 calendar days from the due date of the Form 10-Q (or until February 17, 2025) to regain compliance.
As the Company previously reported, Forvis Mazars, LLP resigned as the Company’s independent registered public accountants on August 9, 2024. The Company is currently in the process of engaging a new independent registered public accounting firm and will use its best efforts to file the Form 10-Q prior to October 21, 2024. If the Company does not file the Form 10-Q in advance of the sixty-day deadline, it intends to timely file a plan to regain compliance with Nasdaq. There can be no assurance, however, that the Company will be able to regain compliance with the listing requirements discussed above or otherwise satisfy the other Nasdaq listing criteria. This notification has no immediate effect on the listing of the Company’s securities on Nasdaq.
About Entero Therapeutics, Inc.
Entero Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company currently has a therapeutic development pipeline with multiple late-stage clinical programs built around three proprietary technologies: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist being developed for gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. Entero Therapeutics is headquartered in Boca Raton, Florida. For more information visit www.enterothera.com.
Forward-Looking Statements
This press release may contain certain statementsrelating to future results which are forward-looking statements. It is possible that the Company’s actual results and financialcondition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements,depending on factors including the Company’s current and future capital requirements and its ability to raise additional funds tosatisfy its capital needs; whether there are delays in the engagement of a new independent registered public accounting firm; whetherthere are any further delays in the preparation and filing of the Company’s Form 10-Q; whether any financing or licensing transactionmay be obtained, completed in an untimely manner, or not at all; whether the Company will be able to realize the expected benefits ofits acquisition of ImmunogenX; the Company’s ability to integrate the assets and contemplated commercial operations acquiredfrom ImmunogenX into the Company’s business; whether the Company will be able to effectively and timely service its debt;whether results obtained in preclinical and nonclinical studies and clinical trials will be indicative of results obtained in future clinicaltrials; whether preliminary or interim results from a clinical trial will be indicative of the final results of the trial; whether theCompany will be able to maintain compliance with Nasdaq’s continued listing criteria and the effect of a delisting from Nasdaq onthe market for the Company’s securities; whether the Company will be able to satisfy the terms of any plan of compliance it submitsto Nasdaq; whether Nasdaq will accept any plan of compliance the Company submits, or provide any other accommodations to the Company;the size of the potential markets for the Company’s drug candidates and its ability to service those markets; and the effects ofthe First Wave Bio, Inc. acquisition, the related settlement and their effect on the Company’s business, operating results and financialprospects. Additional information concerning the Company and its business, including a discussion of factors that could materially affectthe Company’s financial results are contained in the Company’s Annual Report on Form 10-K for the year ended December 31,2023, under the heading “Risk Factors,” as well as the Company’s subsequent filings with the Securities and ExchangeCommission. All forward-looking statements included in this press release are made only as of the date of this press release, and we donot undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequentlyoccur or of which we hereafter become aware.
For more information:
Entero Therapeutics, Inc.
777 Yamato Road, Suite 502
Boca Raton, FL 33431
Phone: (561) 589-7020
info@enterothera.com
Media contact:
Russo Partners
David Schull or Liz Phillips
(347) 956-7697
david.schull@russopartnersllc.com
elizabeth.phillips@russopartnersllc.com